Kim Stuyckens

2.7k total citations
26 papers, 929 citations indexed

About

Kim Stuyckens is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Kim Stuyckens has authored 26 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Kim Stuyckens's work include Fibroblast Growth Factor Research (8 papers), Prostate Cancer Treatment and Research (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Kim Stuyckens is often cited by papers focused on Fibroblast Growth Factor Research (8 papers), Prostate Cancer Treatment and Research (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Kim Stuyckens collaborates with scholars based in United States, Belgium and Spain. Kim Stuyckens's co-authors include An Vermeulen, Mahesh N. Samtani, Juan José Pérez Ruixo, Josep Tabernero, Bob Zhong, Johan W. Smit, Jean‐Charles Soria, Bárbara Adamo, Vijay Peddareddigari and Rodrigo Dienstmann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kim Stuyckens

25 papers receiving 910 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kim Stuyckens United States	15	340	245	214	196	162	26	929
Judith A.M. Wessels Netherlands	23	446 1.3×	248 1.0×	338 1.6×	178 0.9×	138 0.9×	43	2.0k
Paolo Ricchi Italy	18	218 0.6×	75 0.3×	150 0.7×	144 0.7×	107 0.7×	88	1.2k
Gerard J. Davis United States	16	243 0.7×	125 0.5×	188 0.9×	310 1.6×	94 0.6×	53	937
Úna C. McMenamin United Kingdom	23	290 0.9×	476 1.9×	326 1.5×	449 2.3×	333 2.1×	46	1.3k
Karen J. Klamerus United States	17	500 1.5×	382 1.6×	347 1.6×	57 0.3×	142 0.9×	41	1.3k
John Wang United States	22	519 1.5×	292 1.2×	314 1.5×	250 1.3×	221 1.4×	81	1.4k
Paul Toren Canada	19	425 1.3×	681 2.8×	228 1.1×	235 1.2×	272 1.7×	77	1.2k
Marisa Cañadas‐Garre Spain	19	435 1.3×	175 0.7×	256 1.2×	73 0.4×	192 1.2×	44	1.0k
Wayne Frederick United States	19	370 1.1×	164 0.7×	593 2.8×	339 1.7×	418 2.6×	48	1.4k
Daniel R. Saltzstein United States	20	243 0.7×	654 2.7×	219 1.0×	318 1.6×	163 1.0×	87	2.0k

Countries citing papers authored by Kim Stuyckens

Since Specialization

Citations

This map shows the geographic impact of Kim Stuyckens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Stuyckens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Stuyckens more than expected).

Fields of papers citing papers by Kim Stuyckens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Stuyckens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Stuyckens. The network helps show where Kim Stuyckens may publish in the future.

Co-authorship network of co-authors of Kim Stuyckens

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Stuyckens. A scholar is included among the top collaborators of Kim Stuyckens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Stuyckens. Kim Stuyckens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gargano, Cynthia, et al.. (2026). Efficacy and safety of adjunctive treatment with the fatty acid amide hydrolase inhibitor JNJ-42165279 in participants with major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomised study. European Neuropsychopharmacology. 106. 112771–112771.

Dosne, Anne‐Gaëlle, Elodie Valade, Kim Stuyckens, et al.. (2021). Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer. CPT Pharmacometrics & Systems Pharmacology. 11(5). 569–580. 10 indexed citations

Terranova, Nadia, Kim Stuyckens, Anne‐Gaëlle Dosne, et al.. (2021). A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib. Cancer Chemotherapy and Pharmacology. 89(1). 117–128. 10 indexed citations

Asín‐Prieto, Eduardo, et al.. (2021). A quantitative systems pharmacology model for acute viral hepatitis B. Computational and Structural Biotechnology Journal. 19. 4997–5007. 4 indexed citations

Asín‐Prieto, Eduardo, et al.. (2019). Immune network for viral hepatitis B: Topological representation. European Journal of Pharmaceutical Sciences. 136. 104939–104939. 2 indexed citations

Loriot, Yohann, Andrea Necchi, Se Hoon Park, et al.. (2018). Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.. Journal of Clinical Oncology. 36(6_suppl). 411–411. 24 indexed citations

Xu, Xu Steven, Charles J. Ryan, Kim Stuyckens, et al.. (2016). Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics. 56(1). 55–63. 14 indexed citations

Ryan, Charles J., Kim Stuyckens, Matthew R. Smith, et al.. (2015). Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients. Clinical Cancer Research. 21(14). 3170–3177. 50 indexed citations

Dienstmann, Rodrigo, Rastilav Bahleda, Bárbara Adamo, et al.. (2014). Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Cancer Research. 74(19_Supplement). CT325–CT325. 21 indexed citations

10.

Prado, Carla M., Vickie E. Baracos, Jingjie Xiao, et al.. (2014). The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Applied Physiology Nutrition and Metabolism. 39(6). 693–698. 41 indexed citations

11.

Stuyckens, Kim, Fred Saad, Xu Steven Xu, et al.. (2014). Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics. 53(12). 1149–1160. 42 indexed citations

12.

Bahleda, Rastislav, Rodrigo Dienstmann, Bárbara Adamo, et al.. (2014). Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2501–2501. 34 indexed citations

13.

Xu, Steven, Charles J. Ryan, Kim Stuyckens, et al.. (2014). Relationship between abiraterone exposure, prostate-specific antigen (PSA) kinetics, and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) .. Journal of Clinical Oncology. 32(4_suppl). 39–39. 3 indexed citations

14.

Xu, Xu Steven, Kenneth Todd Moore, Paul Burton, et al.. (2012). Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. British Journal of Clinical Pharmacology. 74(1). 86–97. 45 indexed citations

15.

Ruixo, Juan José Pérez, et al.. (2010). Modeling the Effectiveness of Paliperidone ER and Olanzapine in Schizophrenia: Meta‐Analysis of 3 Randomized, Controlled Clinical Trials. The Journal of Clinical Pharmacology. 50(3). 293–310. 9 indexed citations

16.

Xu, Xu Steven, et al.. (2010). Population Pharmacokinetics of Tapentadol Immediate Release (IR) in Healthy Subjects and Patients with Moderate or Severe Pain. Clinical Pharmacokinetics. 49(10). 671–682. 25 indexed citations

17.

Samtani, Mahesh N., An Vermeulen, & Kim Stuyckens. (2009). Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia. Clinical Pharmacokinetics. 48(9). 585–600. 139 indexed citations

18.

Hing, Jeremy, Juan José Pérez Ruixo, Kim Stuyckens, et al.. (2007). Mechanism-based Pharmacokinetic/Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia. Clinical Pharmacology & Therapeutics. 83(1). 130–143. 35 indexed citations

19.

Ruixo, Juan José Pérez, Peter Zannikos, Kim Stuyckens, et al.. (2007). Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743,??Yondelis??) in Cancer Patients. Clinical Pharmacokinetics. 46(10). 867–884. 39 indexed citations

20.

Fetterly, Gerald J., Joel Owen, Kim Stuyckens, et al.. (2007). Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemotherapy and Pharmacology. 62(1). 135–147. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact